Clicky

Relief Therapeutics Hldg Ag(RLFTD)

Description: Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company focuses on clinical-stage programs based on molecules with a history of clinical use and either initial human activity or efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action for respiratory indications, which is in Phase 3 clinical trials for treating COVID-19-induced acute respiratory distress syndrome and moderate to severe COVID-19 lung injury; in Phase 1 clinical trial for the treatment of patients with acute lung injury in other intensive care unit; and in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also developing ACER-001, a proprietary powder formulation of sodium phenylbutyrate, which has completed Phase 3 clinical trial for urea cycle disorders; and in Phase 1 clinical trial for the treatment of maple syrup urine disease. In addition, it is developing APR-TD011, a spray-formulated hypotonic acid-oxidizing solution, which is in Phase 2 clinical trial for treating epidermolysis bullosa. The company was founded in 2013 and is based in Geneva, Switzerland.


Keywords: Medicine Biopharmaceutical Clinical Trial Serious Diseases Covid 19 Acute Respiratory Distress Syndrome Epidermolysis Bullosa Sarcoidosis Acute Lung Injury Pulmonary Sarcoidosis Sodium Phenylbutyrate Urea Cycle Disorders Lung Injury Maple Syrup Urine Disease Acer 001 Spray Formulated Hypotonic Acid Oxidizing Solution Td011 Treatment Of Maple Syrup Urine Disease

Home Page: www.relieftherapeutics.com

BAtiment F2/F3
Geneva, 1202
Switzerland
Phone:


Officers

Name Title
Mr. Jack Weinstein CFO, Treasurer & Pres of Relief U.S.
Mr. Paolo Galfetti COO & Director
Mr. Jeremy Meinen Chief Accounting Officer & VP of Fin. & Admin.
Dr. Nermeen Varawalla DPhil, M.B.A., M.D., MBA, Ph.D. Chief Medical Officer
Mr. Marco Marotta Chief Bus. Officer
Mr. Anthony M. Kim Sr. VP & Head of U.S. Commercial Operations
Mr. Christopher Wick Sr. Director & Head of U.S. Sales
Dr. Dorian Bevec Ph.D. Chief Scientific Officer of AdVita Lifescience
Ms. Drew Cronin-Fine Exec. Director & Head of U.S. Marketing
Dr. Serene Forte M.P.H., Ph.D. Sr. VP & Head of Genetic Medicine

Exchange: OTCQB

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.7602
Price-to-Sales TTM: 26.708
IPO Date:
Fiscal Year End: December
Full Time Employees: 10
Back to stocks